Small Molecules
7 September 2016
Promising new findings for Probiodrug’s Glutaminyl Cyclase – inhibitor in an inflammation animal model7 September 2016
Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop7 September 2016
Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma6 September 2016
vasopharm Announces Enrolment of First Patient In Phase III Traumatic Brain Injury (TBI) Trial5 September 2016
Novel Antibacterial Drug, exeporfinium chloride, Delivers Encouraging Safety, Tolerability and Efficacy Data in US Clinical Trial.3 September 2016
Merck Provides Update on Odanacatib Development Program2 September 2016
ChemoCentryx Reports Initial Results from Ongoing Phase Ib Clinical Trial of CCX872 in Patients with Advanced Pancreatic Cancer2 September 2016
Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo1 September 2016
InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias1 September 2016
Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 20161 September 2016
Array BioPharma Announces FDA Acceptance of Binimetinib NDA for Patients with Advanced NRAS-Mutant Melanoma1 September 2016
Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development31 August 2016
Betagenon AB: Start of Phase IIa Proof-of-Concept Clinical Trial of AMPK Activator O304 in Type 2 Diabetics30 August 2016
Oncternal Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial of TK216 in Ewing Sarcoma30 August 2016
Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress30 August 2016
ARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration30 August 2016
Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers30 August 2016
SIGA Announces Completion of Enrollment and Dosing in the Final Cohort of Phase III Study of TPOXX™ (tecovirimat)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports